RESULTS
by ever-smoking versus never-smoking status. We performed the meta-analyses of the smoking strata within each study and of the study-specific results using inverse-variance weighting (and used the inverse of the standard error squared as the weight). We applied genomic control twice at the study level (to each smoking stratum separately and to the study-level pooled estimates) and also at the meta-analysis level to avoid inflation of the test statistics caused by cryptic population structure or relatedness (see Supplementary Table 1a for study-level estimates). Our application of genomic control at the three stages is likely to be overly conservative because it has recently been shown that in large meta-analyses, test statistics are expected to be elevated under polygenic inheritance even when there is no population structure 12 . The test statistic inflation (λ GC ) before applying genomic control at the meta-analysis level was 1.12 for FEV 1 and 1.09 for FEV 1 /FVC. Genomic inflation estimates increase with sample size, as has been shown for other traits [13] [14] [15] ; the standardized estimates to a sample of 1,000 individuals (λ GC_1,000 ) were 1.002 for FEV 1 and 1.002 for FEV 1 /FVC. Plots of the meta-analysis P values for FEV 1 and FEV 1 /FVC against a uniform distribution of P values expected under the null hypothesis showed deviations which were attenuated, but which persisted, after removal of SNPs in loci reported previously, consistent with additional loci being associated with lung function (Supplementary Fig. 1a ).
Follow-up analysis (stage 2)
Twenty-nine new loci showing evidence of association with lung function (P < 3 × 10 −6 ) in stage 1 were followed up in stage 2 by using in silico data from seven studies and by undertaking additional genotyping in ten studies for the ten highest ranked SNPs (Fig. 1) . Full details of the SNP selection are given in the Online Methods. We performed an inverse-variance-weighting meta-analysis across stages 1 and 2 and obtained two-sided P values for the pooled estimates. Sixteen new loci reached genome-wide significance (P < 5 × 10 −8 ) and showed consistent direction of effects in both stages, comprising 12 new loci for FEV 1 /FVC, 3 new loci for FEV 1 
and 1 new locus reaching
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function Pulmonary function, reliably measurable by spirometry, is a heritable trait reflecting the physiological state of the airways and lungs 1 . Pulmonary function measures are important predictors of population morbidity and mortality [2] [3] [4] and are used in the diagnosis of chronic obstructive pulmonary disease (COPD), which ranks among the leading causes of death in developed and developing countries 5, 6 . A reduced ratio of forced expiratory volume in 1 second (FEV 1 ) to forced vital capacity (FVC) is used to define airway obstruction, and a reduced FEV 1 is used to grade the severity of airway obstruction 7 .
Recently, two large genome-wide association studies (GWAS), each comprising discovery sets of more than 20,000 individuals of European ancestry, identified new loci for lung function 8, 9 . Recognizing the need for larger data sets to increase the power to detect loci of individually modest effect size, we conducted a meta-analysis of 23 lung function GWAS comprising a total of 48,201 individuals of European ancestry (stage 1) and followed up potentially new loci in 17 further studies comprising up to 46,411 individuals (stage 2). We identified 16 additional new loci for lung function and provided evidence corroborating the association of loci previously associated with lung function [8] [9] [10] [11] . Our findings implicate a number of different mechanisms underlying regulation of lung function and highlight loci shared with complex traits and diseases, including height, lung cancer and myocardial infarction.
A r t i c l e s genome-wide significance for both traits ( Fig. 2 and Table 1 ). To assess the heterogeneity across the studies included in stage 1 and 2, we performed χ 2 tests for all 16 SNPs, and none of these SNPs was statistically significant after applying a Bonferroni correction for 16 tests. The sentinel SNPs at these loci were in or near MFAP2
, CFDP1 (16q23.1) and KCNE2-LINC00310 (also known as C21orf82) (21q22.11) ( Supplementary  Fig. 1b,c) . The strongest signals in AGER (rs2070600) 8, 9 and two of the new signals (rs6903823 in ZKSCAN3 and rs2857595, upstream of NCR3) lie within a ~3.8-Mb interval at 6p21.32-22.1 that is characterized by long-range linkage disequilibrium (LD). Nevertheless, the leading SNPs in these regions, which are within the major histocompatibility complex (MHC), were statistically independent (Supplementary Note).
Gene expression
We investigated mRNA expression of the nearest gene for each of the 16 new loci in human lung tissue and a range of human primary cells including lung, brain, airway smooth muscle cells and bronchial epithelial cells. We detected transcripts for all the selected genes in lung tissue except CCDC38, and we also detected transcripts for most genes in airway smooth muscle cells and in bronchial epithelial cells ( Table 2) . As we were unable to detect expression of CCDC38 in any tissue, we also examined expression of SNPRF, which is the gene adjacent to CCDC38 ( Table 2) , and found its expression in all four cell types. TGFB2, MFAP2, EVI1 and MMP15 were expressed in one or more lung cell types but not in peripheral blood mononuclear cells, providing evidence that these genes may show tissue-specific expression.
We assessed whether SNPs in these new regions or their proxies (r 2 > 0.6) were associated with gene expression using a database of expression-associated SNPs in lymphoblastoid cell lines 16 . Four loci showed regional (cis) effects on expression (P < 1 × 10 −7 ; Supplementary Note). A proxy for our sentinel SNP in CFDP1, rs2865531, coincided with the peak of the expression signal for CFDP1, and the strongest proxy for rs6903823 in ZKSCAN3 coincided with the peak of expression for ZSCAN12.
Plausible pathways for lung function involving new loci
The putative function of the genes within, or closest to, the association peaks identify a range of plausible mechanisms for affecting lung function. The most statistically significant new signal for FEV 1 /FVC (P = 7.5 × 10 −16 ) was in the gene encoding MFAP2, an antigen of elastin-associated microfibrils 17 , although correlated SNPs in the region potentially implicate other genes that could plausibly influence lung function, such as CROCC, which encodes rootletin, a component of cilia 18 . Our second strongest new signal, also for FEV 1 /FVC, was in RARB, the gene encoding the retinoic acid receptor β. Rarb-null knockout mice have premature alveolar septation 19 . The third most statistically significant new signal for FEV 1 /FVC, and the most statistically significant new signal for FEV 1 , was in CDC123. Figure 1 Study design. We followed up in stage 2 a total of 34 SNPs showing new evidence of association (P < 3 × 10 −6 ) with FEV 1 and/or FEV 1 /FVC in a meta-analysis of the stage 1 studies. Studies with a combined total of 24,737 individuals undertook genotyping and association testing of the top ten SNPs. Seven studies (marked with an asterisk) with a combined total of 11,275 individuals had genome-wide association data and provided results for up to 34 SNPs. Researchers from GS: SFHS (marked with # ) undertook genotyping on a 32-SNP multiplex genotyping platform and so included the 32 top ranking SNPs (including proxies and both SNPs from regions that showed association with both FEV 1 and FEV 1 /FVC). This assay failed for one SNP (rs3769124), which was subsequently replaced with the thirty-third SNP (rs4762767). We excluded rs2284746 because of poor clustering. Although rs3743563 was chosen as proxy for rs12447804, which had an effective N < 80% in the stage 1 meta-analysis, researchers from BHS2 were unable to genotype rs3743563 and so undertook genotyping for rs12447804 instead. See table 1 for definitions of all study abbreviations.
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This was the only new region to show genome-wide association with both traits. CDC123 encodes a homolog of a yeast cell-division-cycle protein that plays a critical role in modulating eukaryotic initiation factor 2 in times of cell stress 20 . The fourth signal for FEV 1 /FVC is downstream of HDAC4, which encodes a histone deacetylase; reductions in the expression of other histone deacetylases (specifically HDAC2, HDAC5 and HDAC8) have been noted in COPD 21 .
The regions we observed in the MHC are much more difficult to localize, with multiple genes being tagged by the top SNP, including nonsynonymous SNPs in ZKSCAN3, PGBD1, ZSCAN12, ZNF323, TCF19, LTA, C6orf15 and GPANK1 (also known as BAT4) (Supplementary Table 2 ). At 6p21.33, we observed the strongest association with lung function for rs2857595, which is in LD (r 2 = 0.47) with a nonsynonymous SNP in LTA (encoding lymphotoxin α) and with a SNP in the upstream promoter region of TNFA (encoding tumor necrosis factor α) (r 2 = 0.86), both of which are plausible candidates 22, 23 . Our top SNP in MMP15 is in strong LD (r 2 = 1) with a non-synonymous SNP (rs3743563, which has an association with FEV 1 /FVC at P = 1.8 × 10 −7 ) within the same gene. Among the plausible mechanisms implicated by the other new signals of association with lung function reported here is TGF-β signaling; TGFB2 expression is upregulated in bronchial epithelial cells in asthma 24 . The putative function of key genes (as defined by LD with the leading SNP) in each of the 16 loci, and relevant findings from animal models, are summarized in Table 2 and are detailed in Supplementary Table 2 .
Associations with lung function in children
Alleles representing 11 of the 16 new loci showed directionally consistent effects on lung function in 6,281 children (7-9 years of age) ( Supplementary Table 3a ), suggesting that genetic determination of lung function in adults may in part act through effects on lung development, or alternatively, that some genetic determinants of lung growth and lung function decline are shared.
Association of lung function loci with other traits
Although we stratified for ever smoking versus never smoking, we did not adjust for the amount smoked. In order to investigate the possibility that the associations at any of our 16 new regions were driven by an effect of the SNP on smoking behavior, we evaluated in silico data for associations with smoking amount from the Oxford-GlaxoSmithKline (Ox-GSK) consortium 25 for the leading SNPs in these 16 regions. None of these 16 SNPs showed statistically significant association with the number of cigarettes smoked per day ( Supplementary Table 3b ). In addition, in our stage 1 and 2 datasets combined, we assessed whether the estimated effect sizes of the variants on lung function phenotypes differed substantially between ever smokers and never smokers ( Supplementary Table 4 ) across the 16 loci. For the most strongly associated trait at each locus, we tested the SNP interaction with ever smoking versus never smoking. None of the 16 new loci showed a significant interaction (Bonferroni-corrected threshold for 16 independent SNPs P = 0.003125). These analyses suggest that the genetic effects we have identified underlie lung function variability irrespective of smoking exposure.
We adjusted our lung function associations for height, but there are some overlaps between loci associated with height and those associated with lung function. Therefore, we evaluated in silico data for height associations of our new regions in the GIANT consortium 14 dataset. The G allele of rs2284746 (in an intron of MFAP2), which was associated with decreased FEV 1 /FVC, was associated with increased height ( Supplementary Table 3c ).
Given reported associations between lung cancer and either COPD or lung function decline, we also assessed in silico data for sentinel or proxy SNPs in these 16 regions for associations with lung cancer in the International Lung Cancer Consortium (ILCCO) GWAS meta-analysis 26 . Alleles associated with reduced lung function were associated with risk of lung cancer at the strongest available proxy SNP for rs2857595 (upstream of NCR3) at 6p21.33 (rs3099844, r 2 = 0.67) and for the strongest proxy SNP for rs6903823 (a SNP in an intron of ZKSCAN3 and ZNF323) at 6p22.1 (rs209181, r 2 = 0.69) (lung cancer associations at P = 2.2 × 10 −7 and P = 3.4 × 10 −5 , respectively; Supplementary Table 3d ). We saw no significant associations with lung cancer at the other new loci (proxy SNPs were available for 15 of the 16 loci, Bonferroni-corrected P < 0.0033).
In addition to the effects on height, smoking and lung cancer described above, we examined the literature for evidence of associations with other traits for each of the 16 new loci (detailed in Supplementary  Table 2 ). Genome-wide significant associations (P < 5 × 10 −8 ) have been reported in KCNE2 with myocardial infarction 27 and at 6p21.33 near NCR3-AIF1 with neonatal lupus 28 and systemic lupus erythematosus 29 . Other significant complex disease associations have also been noted in the regions of CDC123 (type 2 diabetes 30 ), CFDP1 (type 1 diabetes 31 ) and MECOM (blood pressure 32, 33 ), but with weaker LD (r 2 < 0.3) being seen between the reported SNP and the sentinel SNP for lung function in the region (Supplementary Table 2 ).
Proportion of variance explained by loci discovered to date
Associations in ten loci previously reported for lung function 8, 9 reached genome-wide significance (P < 5 × 10 −8 ) in our stage 1 data, namely loci in or near TNS1, FAM13A, GSTCD-NPNT, HHIP, HTR4, ADAM19, AGER, GPR126, PTCH1 and TSHD4 ( Supplementary Table 5a ). Thus, a total of 26 regions showed genome-wide significant association with lung function in our study. In aggregate, variants at these 26 regions explain approximately 3.2% of the additive polygenic variance for FEV 1 /FVC and 1.5% of the variance for FEV 1 (Supplementary  Note) . Following the approach previously described 34 , we estimated that there are a total of 102 (95% confidence interval 57-155) independent variants with similar effect sizes to the 26 variants we report here. In combination, these 102 variants, comprising 26 discovered variants and 76 putative undiscovered variants, collectively explain around 7.5% of the additive polygenic variance for FEV 1 /FVC and 3.4% of the variance for FEV 1 (Online Methods, Supplementary  Table 6 and Supplementary Note). Cytokine with roles in pro-fibrotic cytokine modulating epithelial repair mechanisms and extracellular matrix homeostasis including collagen deposition 40 .
Major antigen of elastin-associated microfibrils 17 and a candidate for involvement in the etiology of inherited connective tissue diseases.
Deacetylase of histone surrounding DNA thus influencing transcription factor access to the DNA and possibly repressing gene transcription.
Zinc finger transcription factor, encoded as part of MECOM (MDS1-EVI1 complex locus).
Nuclear retinoic acid receptor responsive to retinoic acid, a vitamin A derivative and which also controls cell proliferation and differentiation.
Initially identified as a mediator of spermatogenesis, other family members may have a role in pancreatic development and β-cell proliferation 41 .
Function unknown, although other family members have been identified as having roles in cell signaling, protein degradation and cytoskeleton functions 42 .
Required for efficient cytotoxicity responses by natural killer cells against normal cells and tumors 43 .
Transcription factor involved in cell growth, cell cycle and signal transduction.
Homolog in yeast shown to be a critical control protein modulating eukaryotic initiation factor 2 in times of cell stress.
Potentially diverse roles including cell signaling and migration 44 .
Function unknown, although other family members involved in a diverse array of functions skeletal and motor function 45 .
12 SNRPF Small nuclear ribonucleoprotein F.
Member of a large protease family with diverse functional roles via protease activity and specificity including tissue remodeling, wound healing, angiogenesis and tumor invasion.
Craniofacial development protein 1.
KCNQ1-KCNE2 K+ channels may modulate transepithelial anion secretion in Calu3 airway epithelial cells 46 .
Reference gene 12 GAPDH + + + + + indicates the gene is expressed in the cell type used, and − indicates that we did not detect the gene expression at the mRNA level following 40 cycles of PCR. PCR profiling of gene transcripts in the human lung showed expression of all candidates except CCDC38, for which two sets of primers were designed and tested under different optimization conditions. None of these assays detected expression of CCDC38 in the cell types analyzed. We instead assayed SNRPF, which neighbors CCDC38 and harbors SNPs in strong LD with CCDC38's sentinel SNP. All PCR products were sequence verified. We used GAPDH (encoding glyceraldehyde-3-phosphate dehydrogenase) as a positive control for the complementary DNA, and this gene was expressed in all tissues. Chr., chromosome; HASM, human airway smooth muscle; HBEC, human bronchial epithelial cells; PBMC, peripheral blood mononuclear cells.
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DISCUSSION
In meta-analysis of 23 studies comprising 48,201 individuals of European ancestry and follow up in 17 studies comprising up to 46,411 individuals, we report genome-wide significant associations with an additional 12 regions for FEV 1 /FVC, an additional 3 regions for FEV 1 and 1 additional region associated with both FEV 1 and FEV 1 /FVC. We also confirmed genome-wide association with ten regions previously associated with lung function, bringing to 26 the total number of loci associated with lung function from analyses of these datasets.
Most of the new loci are in regions not previously suspected to have been involved in lung development, the control of pulmonary function or the risk of developing COPD. Elucidating the mechanisms through which these regions influence lung function should lead to a more complete understanding of lung function regulation and the pathogenesis of COPD. Four of the new loci (MFAP2, ZKSCAN3, near NCR3 and near KCNE2) that we showed to be associated with lung function are also associated with other complex traits and diseases (with P < 5 × 10 −8 for the other trait at a SNP having r 2 > 0.3 with the top lung function SNP in the region). Understanding the intermediates underlying these pleiotropic effects could also lead to crucial insights into the pathophysiology of lung disease. One potential explanation is that these loci underlie control of the mechanisms regulating the development and resolution of inflammation and subsequent tissue remodeling in a range of tissues. The effect sizes of the variants in the 26 loci associated with lung function collectively explain a modest proportion of the additive genetic variance in FEV 1 /FVC and in FEV 1 , even after accounting for putative undetected variants with a similar distribution of effect sizes 34 . Our findings are consistent with those from other common complex traits, where it is thought that many as yet unidentified common and rare sequence variants, and potentially structural variants, could explain the remaining heritability 35 . That our study more than doubled the number of loci known to be associated with lung function underlines the utility of large sample sizes to achieve the power to detect common variants associated with complex traits. Nevertheless, it is likely that additional variants with similar effect sizes remain undiscovered 14 . In addition, our study was not designed to detect rare variants or structural variants associated with lung function. Identification of rare variants associated with lung function could be helpful in narrowing the scope of ongoing functional work to those genes most likely to be causally related to the association signals we detected.
Our study focused on cross-sectional measures of lung function. Adult lung function at a particular time point is influenced by the peak lung function achieved by 25-35 years of age as well as the rate of decline of lung function after that peak 36 . The 26 loci now confirmed to be associated with lung function could affect either pre-or postnatal lung development and growth or decline in lung function during adulthood, or both. We showed consistent directions of estimated effects on lung function between adults and children 7-9 years of age for SNPs at 11 of the 16 new loci and 8 of the 10 previously reported loci (Supplementary Table 3a) . The results we show for lung function in children provide some indication that these loci affect lung function development, although studies in larger populations of children would provide greater clarity for SNPs in the new loci. Further investigations will be required in large populations with longitudinal data to delineate the influence of these variants on the rates of development of, and decline in, lung function and on the risk of developing COPD.
Of the sentinel SNPs at the 16 new loci associated with lung function, only rs2284746 (MFAP2) was associated with height in the GIANT consortium 14 dataset. The G allele of rs2284746 was associated with both increased height and reduced lung function. A similar relationship between lung function and height was previously reported for the G allele of rs3817928 in GPR126 (refs. 8, 14) , which is associated with decreased height but with increased FEV 1 /FVC. A further 3 of the 180 loci found to be associated with height 14 showed association (for the 180 loci, we used a Bonferroni-corrected threshold of P = 2.8 × 10 −4 ) with either FEV 1 (CLIC4 and BMP6) or FEV 1 /FVC (PIP4K2B) ( Supplementary Table 3e ). In each case, the allele associated with an increase in height was associated with a decrease in lung function. This is not the case for the association of rs1032296 near HHIP, which has shown consistent directions of effects on lung function and height 11, 14 . However, the strongest SNP associated with height in the HHIP region lies within an intron of HHIP but shows no association with FEV 1 or FEV 1 /FVC. Furthermore, although height is an important predictor of FEV 1 , this is not true for its ratio to FVC 37 . These observations argue against the associations with lung function at these loci being simply caused by incomplete adjustment for height.
We stratified by ever-and never-smoker status in our analyses, and in our investigation of amount smoked in the Ox-GSK consortium 25 , none of the sentinel SNPs in the 16 new regions showed association with the number of cigarettes smoked per day. Additionally, none of these regions was associated with ever smoking in the Ox-GSK consortium data ( Supplementary Table 3b ). Thus, the SNP associations with lung function we observed are unlikely to have arisen simply as a consequence of inadequate adjustment for smoking.
We did not observe any interactions with ever smoking for any of the sentinel SNPs in the 16 new regions that exceeded a Bonferronicorrected significance level (for 16 SNPs). Thus, the effects on lung function of the newly associated variants we identified are apparent in both ever smokers and in never smokers, and the effects of smoking and of these genetic variants may be independent and additive.
In other common complex diseases, follow-up studies that incorporate common genetic risk variants into models to predict disease have not been shown to add substantially to existing risk models, particularly when such models already include family history 38, 39 . The same may also prove to be true for the 26 genetic variants described in this paper, as the effect size of any individual variant is small, but further work is required in this area. The major utility of our findings will be in the knowledge they provide about previously unknown pathways underlying lung function. Elucidating the mechanisms that these genes are involved in will lead to improved understanding of the regulation of lung function and potentially to new therapeutic targets for COPD.
URLs. R, http://www.r-project.org/.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
ONLINE METhODS
Study design. The study consisted of two stages. Stage 1 was a meta-analysis conducted on directly genotyped and imputed SNPs from individuals of European ancestry in 23 studies with a total of 48,201 individuals. Supplementary Table 1a gives the details of these studies. Thirty-four SNPs selected according to the results in stage 1 were followed up in stage 2. The ten leading SNPs were followed up in up to 46,411 individuals of European ancestry, and the remaining 24 SNPs were followed up in a subset of up to 21,674 individuals (Fig. 1) .
Stage 1 samples.
A total of 23 studies, 17 from the SpiroMeta consortium and 6 from the CHARGE consortium, formed stage 1: AGES, ARIC, B58C T1DGC, B58C WTCCC, BHS1, CHS, ECRHS, EPIC (obese cases and populationbased studies), the EUROSPAN studies (CROATIA-Korcula, ORCADES and CROATIA-Vis), FHS, FTC (incorporating the FinnTwin16 and Finnish Twin Study on Aging), Health 2000, Health ABC, KORA F4, KORA S3, NFBC1966, RS-I, RS-II, SHIP and TwinsUK-I (see Supplementary Table 1 for the definitions of all abbreviations). Measurements of spirometry for each study are described in the Supplementary Note. The genotyping platforms and quality-control criteria implemented by each study are described in Supplementary Table 1b. Imputation. Imputation of non-genotyped SNPs was undertaken with MACH 47 , IMPUTE 48 or BIMBAM 49 with pre-imputation filters and parameters as shown in Supplementary Table 1b . SNPs were excluded if the imputation information, assessed using r2.hat (MACH), .info (IMPUTE) or OEvar (BIMBAM), was <0.3. In total, 2,706,349 SNPs were analyzed.
Transformation of data and genotype-phenotype association analysis.
Linear regression of age, age 2 , sex, height and ancestry principal components was undertaken on FEV 1 (milliliters) and FEV 1 /FVC (percent). The residuals were transformed to ranks and then transformed to normally distributed z-scores. These transformed residuals were then used as the phenotype for association testing under an additive genetic model, separately for ever smokers and never smokers. The software used is specified in Supplementary Table 1b . Appropriate tests for association in related individuals were applied where necessary, as described in the Supplementary Note. Meta-analysis of stage 1 data. All stage 1 study effect estimates, both for ever smokers and never smokers, were corrected using genomic control 50 and were oriented to the forward strand of the NCBI build 36 reference sequence of the human genome, consistently using the alphabetically higher allele as the coded allele. Study-specific λ estimates are shown in Supplementary Table 1 . For each study, effect estimates and standard errors for ever smokers and never smokers were meta-analyzed using inverse-variance weighting. Genomic control was applied again to the pooled effect-size estimates for each study. Finally, effect-size estimates and standard errors were combined across studies using an inverse-variance-weighting meta-analysis, and genomic control was applied to the pooled effect-size estimates. To describe the effect of imperfect imputation on power, for each SNP we report the effective sample size (N effective), which is the sum of the study-specific products of the sample size and the imputation quality metric. Meta-analysis statistics and figures were produced using R version 2.9.2 (see URLs).
Selection of SNPs for stage 2.
All regions selected for follow up in stage 2 contained a lead SNP with new evidence of association (all with P < 3 × 10 −6 ) with FEV 1 and/or FEV 1 /FVC, an N effective ≥70% of the total stage 1 sample size and association signals from the surrounding SNPs that were consistent with their correlation (LD) with the leading SNP. Twenty-nine independent regions with a leading SNP meeting these criteria were assessed in stage 2. Regions were defined as independent if the leading SNP from one region was >500 kb from the leading SNP of any other region. Long-range LD was also investigated between leading SNPs of regions in or near the MHC on chromosome 6 (Supplementary Note). For two regions, the leading SNP had an N effective ≥70% but <80% of the stage 1 sample size and, therefore, a proxy SNP from each region (r 2 = 1 and r 2 = 0.97) was also taken forward. For three regions, there were different leading SNPs for FEV 1 and FEV 1 /FVC, and so both leading SNPs were assessed. A total of 34 SNPs were analyzed in stage 2 and are listed in Supplementary Table 5b . Previously reported regions [8] [9] [10] [11] 51, 52 were not followed up. We present in Supplementary Table 5a association test statistics in stage 1 only for relevant SNPs from previously reported regions.
Stage 2 samples. The 34 SNPs were followed up in up to 11,275 individuals from seven studies with in silico data: CARDIA, CROATIA-Split, LifeLines, LBC1936, MESA-Lung, RS-III and TwinsUK-II (Supplementary Table 1) . rs2647044 was not available from TwinsUK-II.
The 34 SNPs were ranked by P value (for association with either FEV 1 or FEV 1 /FVC), and the top ten leading SNPs were selected for follow up by genotyping in up to 35,136 individuals from ADONIX, BHS2, BRHS, BWHHS, Gedling, GS: SFHS, HCS, Nottingham Smokers, NSHD and SAPALDIA (Supplementary Table 1 ). If a SNP in the top ten had an N effective <80%, only the proxy SNP was included in the top ten for follow up. For regions that showed association with both FEV 1 and FEV 1 /FVC, only the leading SNP with the lowest P value for either trait was included if it was within the top ten SNPs. The study design is illustrated in Figure 1 .
Meta-analysis of stage 2 data. All stage 2 studies provided effect estimates for ever smokers and never smokers, apart from Nottingham Smokers, as that study only included smokers. Studies with family data (BHS2 and GS: SFHS) analyzed ever smokers and never smokers together to account for the family correlation, adding the smoking status as a covariate in the model, and therefore provided smoking-adjusted effect estimates. All stage 2 study effect estimates were oriented to the forward strand of the NCBI build 36 reference sequence of the human genome, consistently using the alphabetically higher allele as the coded allele. For each study with separate results for ever smokers and never smokers, effect estimates and standard errors for ever smokers and never smokers were meta-analyzed using inverse-variance weighting. Genomic control was applied to the pooled effect sizes of those studies with in silico data that undertook the analysis genome wide. Effect estimates and standard errors were combined across the stage 2 studies using an inversevariance-weighting meta-analysis.
Combined analysis of stage 1 and stage 2 samples.
A meta-analysis of stage 1 and 2 results was undertaken using inverse-variance weighting. We described associations as genome-wide significant if they had P < 5 × 10 −8 .
PCR expression profiling. The mRNA expression profiles of TGFB2, MFAP2, HDAC4, EVI1, RARB, SPATA9, ARMC2, NCR3, CDC123, LRP1, CCDC38, SNRPF, MMP15, CFDP1, ZKSCAN3, KCNE2 and C10orf11 were determined in human lung tissue and primary cell samples using RT-PCR, including RNA from lung (Ambion/ABI), brain, airway smooth muscle cells and human bronchial epithelial cells (Clonetics42). Primer sequences are listed in Supplementary  Table 2 . Full details are provided in the Supplementary Note.
Lung function associations in our data of SNPs previously associated with lung function. In order to permit comparison of findings with recent studies of relevance to the field, we present association test statistics (in stage 1 only) for relevant SNPs from previously reported regions ( Supplementary Table 5a ). We included the regions (i) reported as showing genome-wide significant association (P < 5 × 10 −8 ) with lung function, (ii) reported as showing genomewide significant association with COPD, providing that there was additional evidence of association with lung function and (iii) DAAM2, which reached borderline significance in the SpiroMeta consortium 9 . Within each of these regions, if multiple SNPs had been reported, we included all relevant SNPs and also the SNP that showed the strongest association in our data.
Association to other traits of lung-function-associated SNPs. Regions associated (P < 5 × 10 −8 ) with lung function or COPD (and also associated with lung function) were looked up for other traits. Where multiple SNPs were reported for different traits or by different investigators, we aimed to include all relevant SNPs, except those having r 2 > 0.9 with another SNP in the region. We also included the SNPs that showed the strongest association in our data for each region. The following related traits were assessed: (i) lung function in children ( Supplementary Table 3a ); (ii) smoking amount and ever smoking versus never smoking in the Ox-GSK consortium 25 dataset ( Supplementary  Table 3b ); (iii) height in the GIANT consortium 14 dataset ( Supplementary  Table 3c ,e); and (iv) lung cancer in the International Lung Cancer Consortium (ILCCO) GWAS meta-analysis 26 ( Supplementary Table 3d ).
Estimation of the number of undiscovered variants and calculation of the proportion of variance explained. We used the approach previously proposed 34 to estimate the number of independent variants associated with lung function measures that have similar effect sizes to the variants already reported and to calculate the proportion of the variance explained by them. We excluded discovery data when estimating effect sizes to avoid winner's curse bias and obtained the number of undiscovered variants using the discovery power to detect the unbiased effect sizes ( Supplementary Table 6 and Supplementary Note).
Additional analyses. The top SNPs from our new loci and their proxies were searched for correlation with known common copy number variants and expression SNPs. Analyses to identify common pathways underlying the association signals for lung function were undertaken using MAGENTA v2 (ref. 53 ) and GRAIL 54 . Full methods and results are given in the Supplementary Note.
